Department of Pharmaceuticals reports major gains across pharma and medtech in 2025
New Delhi: The Department of Pharmaceuticals reported strong progress in affordability, manufacturing and innovation during 2025, with Janaushadhi sales reaching ₹1,409.32 crore till November.
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana expanded to 17,610 functional Jan Aushadhi Kendras across the country. Of these, 2,202 were opened during 2025. The scheme now offers 2,110 medicines and 315 medical devices across 29 therapeutic groups.
During 2024–25, Janaushadhi sales touched ₹2,022.47 crore. This generated estimated savings of about ₹8,000 crore for citizens. In 2025–26 so far, sales of ₹1,409.32 crore have resulted in savings of nearly ₹5,637 crore.
The department said affordable healthcare access improved further through initiatives such as ₹1 Suvidha sanitary napkins. It also revamped the Janaushadhi online portal. The new system allows easy form submission, document uploads and live tracking with geo-tagging.
Under the Production Linked Incentive schemes, the department reported sharp growth in domestic manufacturing. Investments of ₹40,294 crore were made under the PLI Scheme for Pharmaceuticals by September 2025. This far exceeded the original target of ₹17,275 crore.
Production now covers 726 APIs, KSMs and drug intermediates. Of these, 191 were manufactured for the first time in India.
Department of Pharmaceuticals strengthens innovation and medtech ecosystem
The department said India MedTech Expo 2025 reinforced India’s position as a global medtech innovation hub. The three-day event in New Delhi showcased the complete medtech ecosystem. It brought together start-ups, MSMEs, large firms, researchers and hospitals.
The expo recorded a visitor footfall of 12,106 and hosted 2,980 buyer–seller meetings. Officials said this reflected strong industry engagement and export potential.
Under the Promotion of Research and Innovation in Pharma MedTech Sector scheme, seven Centres of Excellence approved 111 research projects by November 2025. The department said evaluation of applications for industry funding was underway. Fund release will begin within the current financial year.
The department also reported progress in bulk drug parks in Gujarat, Himachal Pradesh and Andhra Pradesh. Each state received central grants of ₹1,000 crore. Construction work is ongoing across all three locations.
The Department of Pharmaceuticals said all seven NIPERs ranked among the top 30 pharmacy institutes in the country. It added that 40 faculty members featured in the Stanford Top 2% Scientists list, highlighting strong research output.
